Cargando…

Combination therapy of a PSEN1-selective γ-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemia

Detalles Bibliográficos
Autores principales:	Vandersmissen, Charlien, Prieto, Cristina, Gielen, Olga, Jacobs, Kris, Nittner, David, Maertens, Johan, Segers, Heidi, Cools, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483366/ https://www.ncbi.nlm.nih.gov/pubmed/36700404 http://dx.doi.org/10.3324/haematol.2022.282144

Ejemplares similares

PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia
por: Govaerts, Inge, et al.
Publicado: (2021)

Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia
por: Verbeke, Delphine, et al.
Publicado: (2019)

Selective inhibitors of the PSEN1–gamma-secretase complex
por: Serneels, Lutgarde, et al.
Publicado: (2023)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping
por: Rack, Katrina, et al.
Publicado: (2022)

Evaluation of PSEN1 subunit of the γ-secretase gene in patients with psoriasis vulgaris: a pilot study
por: Bergler-Czop, Beata, et al.
Publicado: (2021)

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling
por: Long, Huideng, et al.
Publicado: (2023)

Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors
por: Trkulja, Kyla L., et al.
Publicado: (2023)

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
por: Papayannidis, C, et al.
Publicado: (2015)

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
por: Binder, Adam F., et al.
Publicado: (2023)

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies
por: Hing, Zachary A., et al.
Publicado: (2016)

Heterozygous mutation of cysteine(528) in XPO1 is sufficient for resistance to selective inhibitors of nuclear export
por: Neggers, Jasper Edgar, et al.
Publicado: (2016)

Identification of Novel Covalent XPO1 Inhibitors Based on a Hybrid Virtual Screening Strategy
por: Shen, Zheyuan, et al.
Publicado: (2022)

Human Presenilin-1 delivered by AAV9 rescues impaired γ-secretase activity, memory deficits, and neurodegeneration in Psen mutant mice
por: Montenegro, Paola, et al.
Publicado: (2023)

Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2
por: Hsu, Simon, et al.
Publicado: (2020)

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
por: Degryse, Sandrine, et al.
Publicado: (2015)

Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing
por: Meyers, Sarah, et al.
Publicado: (2022)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

Gamma secretase inhibitors of Notch signaling
por: Olsauskas-Kuprys, Roma, et al.
Publicado: (2013)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
por: Turner, Joel G., et al.
Publicado: (2016)

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
por: Rosen, Joshua C., et al.
Publicado: (2021)

Gram-Scale Synthesis of a β-Secretase 1 (BACE 1) Inhibitor
por: Allison, Brett D., et al.
Publicado: (2017)

Gamma secretase orthologs are required for lysosomal activity and autophagic degradation in Dictyostelium discoideum, independent of PSEN (presenilin) proteolytic function
por: Sharma, Devdutt, et al.
Publicado: (2019)

APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease
por: Giau, Vo Van, et al.
Publicado: (2019)

Amyloid-β(1–43) cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
por: Perrone, Federica, et al.
Publicado: (2020)

From EST to structure models for functional inference of APP, BACE1, PSEN1, PSEN2 genes
por: Aathi, Muthusankar, et al.
Publicado: (2019)

Effects of γ-secretase inhibitors in mouse colon
Publicado: (2012)

The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression
por: Deng, Manman, et al.
Publicado: (2023)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
por: Pan, Lijia, et al.
Publicado: (2021)

Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels
por: Youn, Kumju, et al.
Publicado: (2017)

Bax inhibitor 1 is a γ-secretase–independent presenilin-binding protein
por: Wu, Shenjie, et al.
Publicado: (2019)

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
por: Tabe, Yoko, et al.
Publicado: (2015)

The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson’s Disease by Inhibiting the NF-κB/NLRP3 Pathway
por: Liu, Shuhan, et al.
Publicado: (2022)

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
por: Govaerts, Inge, et al.
Publicado: (2019)

APP, PSEN1, and PSEN2 Variants in Alzheimer’s Disease: Systematic Re-evaluation According to ACMG Guidelines
por: Xiao, Xuewen, et al.
Publicado: (2021)

Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALL
por: Real, Pedro J., et al.
Publicado: (2008)

TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia
por: Thielemans, Naomi, et al.
Publicado: (2022)

XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis
por: Zhu, Zhi-Chuan, et al.
Publicado: (2019)

The Second-Generation XPO1 Inhibitor Eltanexor Inhibits Human Cytomegalovirus (HCMV) Replication and Promotes Type I Interferon Response
por: Liao, Yueyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4atnafppkolr6qlbrb97rlko82